MetaCap

Emergent BioSolutions (EBS) vs Vicore Pharma AB (VCRE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Vicore Pharma AB is the larger company by market cap ($264.9 million vs $259.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EBS-38.26%VCRE-42.12%
+4%-23%-49%
Jul 6, 20261 yearNov 20, 2026
EBS-37.27%VCRE-31.75%
+2%-21%-45%
Jul 6, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EBS versus VCRE key metrics
MetricEBSVCRE
Share price$5.05$9.41
Market cap$259.65M$264.89M
1-day change-1.94%-5.09%
YTD return-59.14%—
1-year return-49.70%—
5-year return-88.58%—
Forward P/E4.83—
EPS (TTM)$-5.00$-2.04
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$742.90M—
Revenue growth (YoY)-28.81%—
Net income (latest FY)$52.60M—
Gross margin56.09%—
Operating margin13.47%—
Net margin7.08%—
52-week high$14.06$17.80
52-week low$4.36$7.88
Distance from 52-week high-64.08%-47.16%
Analyst consensusnonestrong_buy
Avg. price target upside+98.02%+158.90%
Average volume1.11M23.31K
Shares outstanding51.42M28.16M
Employees90050
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Emergent BioSolutions

EBS stock →

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments.

Health Care · Biotechnology: Pharmaceutical Preparations · 900 employees

About Vicore Pharma AB

VCRE stock →

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.

Health Care · Biotechnology: Pharmaceutical Preparations · 50 employees

EBS vs VCRE FAQ

Which is bigger, Emergent BioSolutions or Vicore Pharma AB?

Vicore Pharma AB (VCRE) is larger, with a market capitalization of $264.89M compared with $259.65M for Emergent BioSolutions (EBS).

Are Emergent BioSolutions and Vicore Pharma AB in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons